Clostridium difficile: Development of a novel candidate vaccine
Clostridium difficile: Development of a novel candidate vaccine
复制标题
DOI：
10.1016/j.vaccine.2012.01.056
复制
发表时间：
2012-06-19
期刊：
影响因子：
5.5
通讯作者：
Pietrobon, Patricia J. Freda
中科院分区：
文献类型：
--
作者：
Foglia, Ginamarie;Shah, Siddhi;Pietrobon, Patricia J. Freda
艰难梭菌已成为北美和欧盟最常见的医院获得性感染。C.艰难梭菌感染（CDI）是目前世界各地和疾病的认识正在增加。在美国.欧盟和加拿大，除了医院诊断的疾病外，社区中也报告了越来越多的CDI。高毒力菌株增加了与CDI相关的发病率和死亡率。目前的治疗方案是次优的。在所有接受CDI治疗的患者中，20%的复发和65%的第二次复发患者成为慢性病例。血清抗毒素A IgG抗体水平升高与无症状C. difficile为疫苗开发提供了理论基础。赛诺菲巴斯德氏C.目前正在开发用于预防原发性疾病的艰难梭菌候选疫苗。目标人群是有CDI风险的成人、计划住院的患者、长期护理/疗养院居民以及需要频繁/长期使用抗生素的合并症成人。(C)2012爱思唯尔有限公司保留所有权利。
Clostridium difficile has become the most frequent hospital-acquired infection in North America and the EU. C. difficile infection (CDI) is present worldwide and disease awareness is increasing. In the US. EU, and Canada, in addition to hospital diagnosed disease, CDI has also been reported with increasing frequency in the community. Hypervirulent strains have increased the morbidity and mortality associated with CDI. Current treatment options are suboptimal. Of all patients treated for CDI, 20% relapse and 65% of those experiencing a second relapse become chronic cases. An association between increased serum levels of IgG antibody against toxin A and asymptomatic carriage of C. difficile provides a rationale for vaccine development. Sanofi Pasteur's C. difficile candidate vaccine is being developed for the prevention of primary disease. The target population is adults at risk of CDI, those with planned hospitalization, long-term care/nursing home residents, and adults with co-morbidities requiring frequent/prolonged antibiotic use. (C) 2012 Elsevier Ltd. All rights reserved.